Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers, today announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference being held at the Sheraton New York Times Square in New York, NY. Management will present on Tuesday, September 9, 2025, at 3:20 pm Eastern Time and will also participate in one-on-one investor meetings.

A live audio webcast of the event will be available online at Erasca.com/events . An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events .

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team's capabilities and experience, further guided by our scientific advisory board which includes the world's leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ERAS
The Conversation (0)

Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.

Monetary Metals Enters into Exclusive Partnership with Streamex  to Create Tokenized Yield-Bearing Gold Products

Monetary Metals Enters into Exclusive Partnership with Streamex to Create Tokenized Yield-Bearing Gold Products

Monetary Metals has signed an agreement with Streamex to provide yield on physical gold bullion with upwards of $1 billion USD in near term lease capacity

Monetary Metals, the pioneer in gold-and-silver-denominated fixed income products, has partnered with Streamex Exchange Corporation ("Streamex"), which recently merged with BioSig Technologies Inc. (Nasdaq: BSGM). Through this collaboration, Monetary Metals will gain exclusive rights to put Streamex's tokenized gold to work earning yield.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
LaFleur Minerals Provides Swanson Gold Deposit and Beacon Mill Restart Update to Produce Gold and Announces Investor Call on June 5

LaFleur Minerals Provides Swanson Gold Deposit and Beacon Mill Restart Update to Produce Gold and Announces Investor Call on June 5

LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) ("LaFleur Minerals" or the "Company") is pleased to provide the results of its recent exploration programs, including an update on its diamond drilling and bulk sampling plans at its district-scale Swanson Gold Project ("Swanson"), positioned in the prolific Abitibi Gold Belt (Figure 1). The Company is also fast-tracking the restart of its 100%-owned, 750 tonne per day ("tpd") Beacon Gold Mill ("Beacon") in Val-d'Or, Québec, and has received significant interest from several groups for the purpose of financing the mill restart as well as to offtake material and support the ramp-up to full production with the goal to be generating cash flow by early 2026.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Reward Gold Mine Project Update

Vertex Minerals Limited Reward Gold Mine Project Update

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) process plant achieves 60% throughput rate of name plate capacity during processing campaigns while plant commissioning is ongoing with modifications to suit future Reward underground ore feed .

Vertex's Executive Chairman, Roger Jackson commented: "Its pleasing to see we have now almost fully tuned the plant to cater for a wider range of feed stock material. We are now gaining confidence in the processing and gold grade in the surface stockpiles, the fact they are sitting adjacent to the plant and offer an inexpensive feed source is a real advantage to the plant commissioning process.

"The processing of the surface stockpile material has presented some real challenges with the way the old stockpile material breaks down causing frequent blockages in piping. These blockages have hindered the plant availability and throughput, however, the processing team have worked diligently to overcome a vast number of issues in a short period of time.

"Our technical team and operators have been implementing low-cost components and strategies to minimise the fine material into the process. Whilst this has set us back in time with moving to cash flow it is important to note that our main game is mining the Reward high grade gold mine material.

Delays due to plant tuning today should translate to higher efficiencies earlier in the mine plan "Meanwhile our underground team has been busy preparing the historical workings in anticipation of the arrival of our TD1 jumbo drill rig with dewatering, ground support and re-entry tasks underway.

The TD1 jumbo is a crucial piece of mining equipment that will herald the start of a new and prosperous era of mining at the historical Reward Gold Mine.

"Every day I am excited to see the progress of development of the mine, and I look forward to updating investors as and when new news comes to hand"

Over the last 10 weeks the process plant has been steadily ramping up its through put capacity through the commissioning process.

Modifications to the plant include:

- Reducing the clearance in the jaw crusher.

- Dampeners over the sorting screen.

- Increasing the gold concentrate resident time in the Falcon concentrator.

- Increasing recycling load in the regrind mill.

- Adjusting water flows for different circuits in the plant.

- Reducing throughput density on the sand line.

These modifications have been important in increasing the plant utilisation and increasing throughput towards nameplate capacity and availability.

Further modifications and improvements have been identified in the following areas:

- A pre-screening scalper to reduce fines in the crushing system.

- Pre-screening oversize fines material to the re-grind mill prior to the Falcon concentrator

- Tails line (sand line) valves and performance review

- Tails hopper agitator unit

These improvements are planned for integration into the process plant over the next 6 weeks.

Commissioning of the plant using the existing low-grade surface stockpiles has initially enabled modest first concentrate production, allowing Vertex the opportunity to optimise the gold collection processes. A small sample of gold has been sent for refining and sale to test the process. A larger size gold concentrate batch is building as throughput increases. It will be dispatched for refining and sale when worthwhile volumes are obtained.

The low-grade surface stockpile material has been an important source of inexpensive feed material to commission the plant, providing invaluable processing information and support for the training of the new workforce. Further it has offered a rare opportunity to de-risk and optimise the processing flowsheet prior to commencement of mining high-grade underground ore from the Reward mine.

Long lead underground equipment has been ordered, including a TD1 jumbo drill rig (refer VTX ASX 4 March announcement) which is due to arrive from Kalgoorlie in 6 weeks. The arrival of the TD1 jumbo drill will be a key milestone in the development of the Reward mine, signalling a significant shift towards underground mining, and subsequently, underground ore feed into the process plant. Management continues to source other capital items required to furnish and operate the Reward mine.

Vertex continues to progress the Reward mine towards underground mining. Dewatering has commenced of old headings in preparation for the arrival of recently ordered underground mining equipment. Check scaling and assessment of historical ground support has been completed throughout historical areas of the mine.

Areas of concern have been identified and remediated where appliable. Additional ground support will be installed when the TD1 jumbo drill rig has arrived and has been commissioned on site.

*To view the Mineral Resource Estimate, please visit:
https://abnnewswire.net/lnk/9C06B296



About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
North Bay Resources Announces Discovery of Mass Tonnage Gold Deposit up to 149m  Grading 0.95 g/t Au, Fran Gold Project, British Columbia

North Bay Resources Announces Discovery of Mass Tonnage Gold Deposit up to 149m Grading 0.95 g/t Au, Fran Gold Project, British Columbia

North Bay Resources, Inc. (the " Company " or " North Bay ") (OTC: NBRI) is pleased to announce analyses and compilation of prior exploration work at the Fran Gold Project has resulted in the discovery of a mass tonnage gold deposit. This includes review of diamond drilling in 2001, 2005, 2006, 2012, and 2018 as well as geochemical, geophysical and 3D modelling data. Past exploration and development, including over 18,000m (55,000ft.) of diamond drilling, has shown very large intercepts of up to 149m (489 feet) of 0.95 gram per ton gold. The deposit area has been identified to be in excess of 1000m x 100m x 300m within a known strike length of 1700m. This represents an exploration potential of 79,500,000 tonnes at a specific gravity of 2.65. At an average grade of 0.8 grams per tonne the current potential is 2M ounces. There is sufficient data to immediately proceed with a NI 43-101 Compliant Mineral Resource Estimate . The Fran Gold Project is next to Centerra Gold's (TSX:CG) Mt. Milligan Project, with Reserves of 264Mt grading 0.3 gram per tonne gold and 0.2% copper and proximate to Artemis Gold's (TSXV:ARTG) Blackwater Mine, with Proven and Probable Reserves of 334Mt grading 0.8 grams per tonne gold. Both Mt. Milligan and the Blackwater Mine are two of the largest new mines in North America in the modern era. The Blackwater Mine has a Measured and Indicated Resource in excess of 10M ounces of gold.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus. This first-in-class blood test is available from Thursday, 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of 1Q CY2025.

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×